272 related articles for article (PubMed ID: 28291571)
1. The Los Angeles County hub-and-provider network for promoting the sustained use of extended-release naltrexone (XR-NTX) in Los Angeles County (2010-2015).
Cousins SJ; Crèvecoeur-MacPhail D; Kim T; Rawson RA
J Subst Abuse Treat; 2018 Feb; 85():78-83. PubMed ID: 28291571
[TBL] [Abstract][Full Text] [Related]
2. A demonstration project implementing extended-release naltrexone in Los Angeles County.
Cousins SJ; Denering L; Crèvecoeur-MacPhail D; Viernes J; Sugita W; Barger J; Kim T; Weimann S; Rawson RA
Subst Abus; 2016; 37(1):54-62. PubMed ID: 26158698
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County.
Cousins SJ; Radfar SR; Crèvecoeur-MacPhail D; Ang A; Darfler K; Rawson RA
J Subst Abuse Treat; 2016 Apr; 63():66-71. PubMed ID: 26823295
[TBL] [Abstract][Full Text] [Related]
4. Extended-release naltrexone for opioid use disorder started during or following incarceration.
Lincoln T; Johnson BD; McCarthy P; Alexander E
J Subst Abuse Treat; 2018 Feb; 85():97-100. PubMed ID: 28479011
[TBL] [Abstract][Full Text] [Related]
5. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
[TBL] [Abstract][Full Text] [Related]
6. A pilot randomized controlled trial of medication adherence therapy: Psychosocial leverage using a significant other (MAT-PLUS) for individuals on extended-release naltrexone.
Wenzel K; Thomas J; Carrano J; Stidham J; Fishman M
J Subst Use Addict Treat; 2024 Aug; 163():209366. PubMed ID: 38636807
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.
Korthuis PT; Lum PJ; Vergara-Rodriguez P; Ahamad K; Wood E; Kunkel LE; Oden NL; Lindblad R; Sorensen JL; Arenas V; Ha D; Mandler RN; McCarty D;
Addiction; 2017 Jun; 112(6):1036-1044. PubMed ID: 28061017
[TBL] [Abstract][Full Text] [Related]
8. Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
Hartung DM; McCarty D; Fu R; Wiest K; Chalk M; Gastfriend DR
J Subst Abuse Treat; 2014 Aug; 47(2):113-21. PubMed ID: 24854219
[TBL] [Abstract][Full Text] [Related]
9. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry.
Saxon AJ; Akerman SC; Liu CC; Sullivan MA; Silverman BL; Vocci FJ
Addiction; 2018 Aug; 113(8):1477-1487. PubMed ID: 29493836
[TBL] [Abstract][Full Text] [Related]
10. Healthcare utilization and costs associated with treatment for opioid dependence.
Shah A; Duncan M; Atreja N; Tai KS; Gore M
J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915
[TBL] [Abstract][Full Text] [Related]
11. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
Murphy SM; Jeng PJ; Poole SA; Jalali A; Vocci FJ; Gordon MS; Woody GE; Polsky D
Addict Sci Clin Pract; 2020 Apr; 15(1):15. PubMed ID: 32321570
[TBL] [Abstract][Full Text] [Related]
12. Assessing and improving organizational readiness to implement substance use disorder treatment in primary care: findings from the SUMMIT study.
Ober AJ; Watkins KE; Hunter SB; Ewing B; Lamp K; Lind M; Becker K; Heinzerling K; Osilla KC; Diamant AL; Setodji CM
BMC Fam Pract; 2017 Dec; 18(1):107. PubMed ID: 29268702
[TBL] [Abstract][Full Text] [Related]
13. Extended-release naltrexone for youth with opioid use disorder.
Mitchell SG; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
J Subst Abuse Treat; 2021 Nov; 130():108407. PubMed ID: 34118699
[TBL] [Abstract][Full Text] [Related]
14. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.
DeFulio A; Everly JJ; Leoutsakos JM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
Drug Alcohol Depend; 2012 Jan; 120(1-3):48-54. PubMed ID: 21782353
[TBL] [Abstract][Full Text] [Related]
15. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
[TBL] [Abstract][Full Text] [Related]
16. Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
Nunes EV; Bisaga A; Krupitsky E; Nangia N; Silverman BL; Akerman SC; Sullivan MA
Addiction; 2020 Feb; 115(2):239-246. PubMed ID: 31313402
[TBL] [Abstract][Full Text] [Related]
17. Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual.
Soares WE; Wilson D; Rathlev N; Lee JD; Gordon M; Nunes EV; O'Brien CP; Friedmann PD
J Subst Abuse Treat; 2018 Feb; 85():66-69. PubMed ID: 28576389
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.
Jalali A; Jeng PJ; Polsky D; Poole S; Ku YC; Woody GE; Murphy SM
J Subst Abuse Treat; 2022 Oct; 141():108835. PubMed ID: 35933942
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
Murphy SM; Jeng PJ; McCollister KE; Leff JA; Jalali A; Shulman M; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
Addiction; 2021 Dec; 116(12):3444-3453. PubMed ID: 33950535
[TBL] [Abstract][Full Text] [Related]
20. Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.
Jarvis BP; Holtyn AF; Berry MS; Subramaniam S; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
J Subst Abuse Treat; 2018 Feb; 85():38-44. PubMed ID: 28449955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]